Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares grows in line with its trailing trend
Q2 FY2026 weighted avg shares of 157.7M shares rose 3.7% year over year, in line with the +3.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.7% toward the trailing-twelve-month pace of +3.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 151.72M USD
- Year-over-year change
- +3.1%
- 4-year CAGR
- +2.0%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 151.72M | +3.1% |
| FY2024 | 2024-12-31 | 147.1M | +1.9% |
| FY2023 | 2023-12-31 | 144.38M | +1.3% |
| FY2022 | 2022-12-31 | 142.52M | +1.5% |
| FY2021 | 2021-12-31 | 140.35M | — |
Weighted Avg Shares vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 weighted avg shares of 154.7M shares is the 2nd highest of the 10 companies compared; the peer median is 103.26M shares.
- Its year-over-year change of +3.8% is the 8th highest of 10, against a peer median of +13.4%.
- Over three fiscal years its annual growth of +2.1% compares with a peer median of +24.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 185.87M | +1.7% | +5.0% | |
| LTM Jun 2026 | 154.7M | +3.8% | +2.1% | |
| LTM Sep 2026 | 126.24M | +15.3% | +24.4% | |
| LTM Mar 2026 | 122.33M | +2.3% | +5.8% | |
| LTM Jun 2026 | 110.81M | +34.8% | +125.3% | |
| LTM Jun 2026 | 103.26M | +16.4% | +12.2% | |
| LTM Mar 2026 | 88.85M | +4.6% | +28.8% | |
| LTM Jun 2026 | 79.68M | +45.9% | +135.7% | |
| LTM Sep 2026 | 43.89M | +7.8% | +19.3% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | 37.84M | +13.4% | +223.8% |
| Peer median (excluding ADPT) | 103.26M | +13.4% | +24.4% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.34M | 185.31M | 170.28M | 178.96M | 276.98M |
| Cost of Revenue | 49.3M | 57.91M | 75.55M | 72.08M | 71.36M |
| Gross Profit | 105.04M | 127.4M | 94.72M | 106.88M | 205.62M |
| Gross Margin | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% |
| Research & Development | 142.34M | 141.76M | 122.12M | 102.95M | 93.77M |
| Selling, General & Admin | 169.97M | 184.13M | 172.51M | 157.57M | 167.27M |
| Operating Expenses | 314.01M | 327.59M | 321.76M | 269.43M | 262.74M |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| EBITDA | (193.35M) | (175.21M) | (189.27M) | (128.76M) | (29.85M) |
| EBITDA Margin | -125.3% | -94.6% | -111.2% | -71.9% | -10.8% |
| Operating Income | (208.97M) | (200.19M) | (227.04M) | (162.55M) | (57.12M) |
| Operating Margin | -135.4% | -108.0% | -133.3% | -90.8% | -20.6% |
| Interest Income | 1.67M | 4.06M | 15.53M | 14.53M | 9.44M |
| Interest Expense | 0 | 4.24M | 13.8M | 11.58M | 11.78M |
| Other Income / Expenses | 1.67M | (182K) | 1.73M | 2.95M | (2.33M) |
| Income Before Tax | (207.3M) | (200.37M) | (225.3M) | (159.6M) | (59.46M) |
| Pre-Tax Margin | -134.3% | -108.1% | -132.3% | -89.2% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.49M) | (59.5M) |
| Net Margin | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
| EPS (Basic) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| EPS (Diluted) | (1.46) | (1.00) | (1.56) | (1.08) | (0.39) |
| Weighted Avg Shares | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
| Weighted Avg Shares (Diluted) | 140.35M | 142.52M | 144.38M | 147.1M | 151.72M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.